Inclisiran

ATLANTA — For patients with atherosclerotic CVD, an inclisiran-first strategy was associated with greater lowering of LDL compared with the usual care, researchers reported at the American College of Cardiology Scientific Session.

Healio | Cardiology Today has compiled a list of the top headlines in cardiology of July 2023.

The FDA approved a label update for inclisiran to include people with elevated LDL and other risk factors such as hypertension and diabetes who have not experienced a CV event, Novartis announced.

CHICAGO — In adults with atherosclerotic CVD or a risk equivalent, twice-yearly inclisiran injections were associated with a 44% reduction in LDL that was sustained over 4 years with no new safety signals observed, researchers reported.

LDL reduction is the major focus in the primary and secondary prevention of atherosclerotic CVD.

Inclisiran effectively and safely lowered LDL in patients with hyperlipidemia and prior cerebrovascular disease, according to a pooled analysis of the three ORION trials presented at the National Lipid Association Scientific Sessions.

As the COVID-19 pandemic continued to dominate the news, more was learned about its CV implications over the past year. However, the year also featured a number of important developments in other realms of cardiology.

Last week’s top story in cardiology was about the FDA approval of Leqvio for LDL lowering. According to the manufacturer, the drug is administered twice a year after the initial dose and a follow-up dose at 3 months.